Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its previously announced tender offer to acquire all of the outstanding shares of Dionex Corporation (NASDAQ: DNEX) for $118.50 per share in cash ("the Offer") has been extended and will now expire at 12:00 midnight, New York City time, at the end of Wednesday, February 16, 2011, unless further extended. All other terms and conditions of the Offer remain unchanged.
As of 5:00 p.m., New York City time, on January 13, 2011, approximately 3,466,729 shares of Dionex common stock, representing approximately 19.79% of all outstanding shares, had been tendered into and not withdrawn from the offer.
The transaction is subject to the satisfaction of customary closing conditions, including applicable regulatory approvals. As previously announced on January 10, 2011, the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended) expired, satisfying one of these conditions. The company is in the process of seeking similar clearances under antitrust laws of other jurisdictions, and anticipates completing the acquisition later in the first quarter of 2011.
Thermo Scientific MAS Omni Infectious Controls launched to assess the performance of serological assays